Drug Trial Radar · NCT05569954
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,484
Actual
Start
Nov 7, 2022
Primary completion
Oct 30, 2023
Study completion Feb 7, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23, and that V116 is superior to PPSV23 for the 9 serotypes unique to V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in unique V116 serotypes, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).
Conditions
- Pneumococcal Disease
Interventions
V116Biological
Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
PPSV23Biological
Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)Time frame: Up to 5 days postvaccination
- Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days postvaccination
- Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)Time frame: Up to 6 months postvaccination
- Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116Time frame: Day 30 postvaccination
- Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116Time frame: Baseline (Day 1) and Day 30 postvaccination
Locations
55 sites in 11 countries. Site status is shown where the registry gives one.
Fundacion Estudios Clinicos ( Site 0200)
Rosario, Santa Fe Province, Argentina
Paratus Clinical Research Western Sydney ( Site 1500)
Blacktown, New South Wales, Australia
Northern Beaches Clinical Research ( Site 1502)
Brookvale, New South Wales, Australia
Paratus Clinical Research Brisbane ( Site 1501)
Albion, Queensland, Australia
IPS Centro Científico Asistencial S.A.S ( Site 0407)
Barranquilla, Atlántico, Colombia
Fundacion Valle del Lili- CIC ( Site 0415)
Cali, Valle del Cauca Department, Colombia
Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901)
Hamburg, Germany
klinikum rechts der isar der technischen universität münchen ( Site 0904)
München, Bavaria, Germany
InfektioResearch ( Site 0903)
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Koeln ( Site 0900)
Cologne, North Rhine-Westphalia, Germany
Medizentrum Essen Borbeck ( Site 0902)
Essen, North Rhine-Westphalia, Germany
Rambam Health Care Campus ( Site 1002)
Haifa, Israel
Hadassah Medical Center-Clinical Reaserch Unit ( Site 1004)
Jerusalem, Israel
Meir Medical Center-Infectious unit ( Site 1003)
Kfar Saba, Israel
Sheba Medical Center ( Site 1000)
Ramat Gan, Israel
Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1001)
Sakhnin, Israel
Optimal Clinical Trials ( Site 1600)
Auckland, New Zealand
P3 Research - Palmerston North ( Site 1602)
Palmerston North, Manawatu-Wanganui, New Zealand
P3 Research - Lower Hutt ( Site 1601)
Lower Hutt, Wellington Region, New Zealand
The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 1802)
Seoul, South Korea
Asan Medical Center ( Site 1809)
Seoul, South Korea
The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 1806)
Seoul, South Korea
Hallym University Kangnam Sacred Heart Hospital ( Site 1807)
Seoul, South Korea
Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805)
Seoul, South Korea
Korea University Guro Hospital ( Site 1800)
Seoul, South Korea
Wonju Severance Christian Hospital ( Site 1808)
Wŏnju, Kang-won-do, South Korea
Chonnam National University Hospital-Infectious Diseases ( Site 1811)
Gwangju, Kwangju-Kwangyokshi, South Korea
Korea University Ansan Hospital ( Site 1801)
Ansan-si, Kyonggi-do, South Korea
Soon Chun Hyang University Bucheon Hospital ( Site 1812)
Bucheon-si, Kyonggi-do, South Korea
Hallym University Dongtan Sacred Heart Hospital ( Site 1813)
Hwaseong-si, Kyonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital-Internal Medicine ( Site 1803)
Suwon, Kyonggi-do, South Korea
Dong-A University Hospital ( Site 1810)
Busan, Pusan-Kwangyokshi, South Korea
Kyungpook National University Chilgok Hospital-Division of Infectious Diseases ( Site 1804)
Deagu, Taegu-Kwangyokshi, South Korea
Chungnam national university hospital ( Site 1814)
Junggu, Taejon-Kwangyokshi, South Korea
Centre d'Atenció Primària Vallcarca - Sant Gervasi ( Site 1101)
Barcelona, Spain
EAP Sardenya ( Site 1102)
Barcelona, Spain
Hospital La Princesa-Clinical Pharmacology ( Site 1115)
Madrid, Spain
EBA CENTELLES ( Site 1100)
Centelles, Catalonia, Spain
Hospital Universitario Getafe ( Site 1111)
Getafe, Madrid, Comunidad de, Spain
Fundación Oftalmologica del Mediterraneo-Vaccine Research ( Site 1118)
Valencia, Valenciana, Comunitat, Spain
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.